Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.

Our analysis suggests that IVA provides sustained clinical benefits in people with CF over a follow-up period of approximately 8 years. These findings reinforce the existing real-world evidence that IVA can slow disease progression and decrease the healthcare burden of CF over the long term.